TerminatedNot Applicable

Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting

Stopped: Failure to accrue

United States18 participantsStarted 2021-04-29

Plain-language summary

This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.

Who can participate

Age range4 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects who are scheduled to be admitted for chemotherapy administration and who will have at least one additional cycle of the same chemotherapy * Chemotherapy regimens must include moderate and/or severe emetogenic chemotherapy Exclusion Criteria: * Significant developmental delays that would prohibit participation * Infection or severe dermatological condition of ear * Uncontrolled or severe infection * No implanted electrical device is permitted * Pregnancy * Severe cardiopulmonary disease * Diagnosis of hemophilia or other bleeding disorders * Diagnosis psoriasis vulgaris

What they're measuring

Baxter Retching Faces Scale

Timeframe: From the date of baseline assessment up to 7 days after completion of intervention ( day 13)

Change in Rhodes Index of Nausea, Vomiting and Retching (INVR)

Timeframe: From the date of baseline assessment and during the intervention (up to day 5)

Assessment of Rescue Medication

Timeframe: From the date of baseline assessment up to 7 days after completion of intervention ~ day 13

Trial details

NCT IDNCT05143554

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-23

View on ClinicalTrials.gov More Chemotherapy-induced Nausea and Vomiting trials